$INMD

Inmode gains on report Steel Partners made offer for majority stake

This article reports that Inmode shares rose following unconfirmed news that Steel Partners, a diversified holding company, had made an offer to acquire a majority stake in the aesthetic medicine device manufacturer. The news was first reported by Israeli news outlet Calcalist, though there was no official confirmation from either company.

Original reporting
Published Jan 31, 2026, 3:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jan 31, 2026, 4:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$INMD
Bullish
medium confidence
Mentioned
$INMD
alphai data visualization · based on MSN
Decision brief

The 30-second read

$INMDBullishMed
01

Why it matters

If confirmed, the acquisition could lead to increased stock volatility and potential upward price movement for INMD. The market is currently reacting based on speculation.

02

Market read

The news is highly relevant for traders interested in M&A activity within the medical device sector, especially those trading INMD shares.

03

What to watch

Potential regulatory hurdles or anti-trust issues could delay or block the acquisition, limiting the upside.

Timing: Immediate to short-term (next 1-2 weeks)

Background

Steel Partners reportedly made an offer for a majority stake in Inmode, a leading aesthetic medicine device manufacturer. The news was first reported by Calcalist, an Israeli news outlet, but remains unconfirmed by the companies involved.

Company-level read

Ticker impact

$INMDBullishMedium confidence
Context

High relevance due to recent acquisition rumors

Expected impact

Moderate upward price movement within the next 1-2 weeks.

Evidence & confidence

The rumor is unconfirmed, but market sentiment is bullish, which could lead to short-term gains.

Market effects

Potential positive impact on the medical device and aesthetic sectors due to M&A activity

Primarily affecting US and Israeli markets where Inmode and Steel Partners operate

Limited, as the news pertains to specific companies and sectors

Counterpoint

The acquisition rumor may be false or overhyped, leading to a quick reversal if official confirmation is not received.

Key entities

  • Inmode

    Aesthetic medicine device manufacturer.

  • Steel Partners

    Diversified holding company potentially making an acquisition offer.

Related articles

$INMDMedAI 8/10

InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025

InMode Ltd. (Nasdaq: INMD) reported Q2 2026 GAAP revenues of $95.6M, unchanged vs Q2 2025. Consumables and service rose 13% to $22.3M. GAAP net income was $17.1M ($0.29/diluted share). Cash and equivalents plus marketable securities totaled $501.1M at June 30, 2026. FY2026 outlook: revenues $365M-$375M and non-GAAP EPS $1.29-$1.34.

$INMDMed

InMode Ltd. (INMD): Financial results for Q2 2026

InMode Ltd. (INMD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 YOKNEAM, Israel, August 5, 2026 - InMode Ltd. (Nasdaq: INMD) (“InMode”) , a leading global provider of innovative medical techno

$INMDMed

InMode Confirms Receipt of Unsolicited Proposal

InMode Ltd. (NASDAQ: INMD) said its board received an unsolicited acquisition proposal from Steel Partners Holdings L.P., dated July 9, 2026. A special committee of independent directors will review the proposal with legal and financial advisors. The committee said it will not comment further for now.

$INMDMedAI 9/10

InMode Shares Jump After Steel Partners Tables Higher Takeover Proposal (INMD)

InMode Ltd (INMD) shares rose about 4% premarket after Steel Partners Holdings proposed to buy the medical aesthetics company for $16.75 per share in cash, a 20% premium to $13.95 and above a prior $16.20 bid by CEO Moshe Mizrahy. Steel Partners urged an independent committee, questioned governance and possible MNPI around share purchases, and cited 2026 adj. EBITDA of $65M vs guidance $73M-$78M.

$INMDHighAI 9/10

InMode stock surges on Steel Partners’ $16.75 buyout offer By Investing.com

InMode Ltd (NASDAQ:INMD) shares rose about 4% premarket after Steel Partners Holdings offered to buy the company for $16.75 per share in cash. Steel Partners, a major shareholder, cited a 20% premium to $13.95 and said it would allow rollover of up to 40% of equity into Steel-owned InMode. It urged an independent committee, challenged CEO Moshe Mizrahy, and referenced 2026 adjusted EBITDA of $65 million versus guidance of $73 million to $78 million.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.